![](https://www.ecfs.eu/sites/default/files/logos-third-party/Celtaxsys%20Logo%202018%20June.jpg?fid=1935)
Thursday 7 June 2018 07:15-08:15 Amphitheatre | Inflammation in cystic fibrosis: the next frontier Moderator: Stuart Elborn, London, UK |
---|---|
07:15 – 07:30 | Pathophysiology of lung inflammation in CF – Marcus Mall, Berlin, DE |
07:30 –07:45 | Clinical trials addressing CF inflammation and their limitations – Jennifer Taylor-Cousar, Denver, US |
07:45 – 08:00 | Current approaches – Design of acebilustat phase 2b study (EMPIRE CF) – Steven M. Rowe, Birmingham, US |
08:00 – 08:15 | Discussion and questions & answers |
![](https://www.ecfs.eu/sites/default/files/logos-third-party/Vertex_Platinum.jpg?fid=1277)
Thursday 7 June 2018 12:30-14:00 Blue Hall | Shifting the paradigm in cystic fibrosis management: current and future Moderator: Marcus Mall, Berlin, DE |
---|---|
12:30 – 12:45 | Welcome and introduction – Marcus Mall, Berlin, DE |
12:45 –13:05 | Cystic fibrosis: navigating the disease trajectory – Claire Wainwright, Brisbane, AU |
13:05 – 13:25 | Current and future management strategies: the evidence – Jane Davies, London, UK |
13:25 – 13:45 | Future thinking: assessing effectiveness in practice – Barry Plant, Cork, IE |
13:45 – 14:00 | Questions & moderator’s close |
![](https://www.ecfs.eu/sites/default/files/logos-third-party/Chiesi_Logo_Cyan_650.jpg?fid=1936)
Friday 8 June 2018 12:30-14:00 Amphitheatre | Making a difference in cystic fibrosis daily challenges Moderator: Harry Heijerman, Utrecht, NL |
---|---|
12:30 – 13:00 | Preventing CF complications – Harry Heijerman, Utrecht, NL |
13:00 –13:30 | Nebulized antibiotic therapy – yesterday and nowadays – Carsten Schwarz, Berlin, DE |
13:30 – 14:00 | Dealing with the challenges of an ageing CF population – Stuart Elborn, London, UK |
![](https://www.ecfs.eu/sites/default/files/logos-third-party/Vertex_Platinum.jpg?fid=1277)
Friday 8 June 2018 12:30-13:30 Annex B | From bench to bedside: Exploring in vitro to in vivo correlation of CF models Moderator: Mark Higgins, London, UK |
---|---|
12:30 – 12:40 | Welcome and introduction – Mark Higgins, London, UK |
12:40 –13:15 | Rationale, science, and robustness of CF in vitro assays to identify responsive mutations – Paul Negulescu, San Diego, USA Does improved CFTR function in vitro translate into improvement in clinical outcomes? - Charlotte McKee, San Diego, USA |
13:15 – 13:30 | Questions & moderator’s close |